No description available.

No description available.

Ischaemia-reperfusion (IR) injury is caused by the re-introduction of oxygen to organs, following periods of reduced blood flow (ischaemia). Whilst re-establishing blood flow (reperfusion) to the heart following myocardial infarction is vital for organ survival, this paradoxically leads to tissue damage. Mitochondria are at the heart of IR injury, with succinate dehydrogenase (SDH) a major player in orchestrating the damage. Succinate accumulates during ischaemia and is rapidly oxidised by SDH upon reperfusion, producing reactive oxygen species (ROS), leading to cellular death. I have investigated the development of drugs, aimed at targeting succinate metabolism to ameliorate IR injury. I firstly screened a range of compounds for their ability to inhibit SDH, having been chosen for their similar structures to succinate or the classical SDH inhibitor, malonate. Interestingly, only malonate and oxaloacetate showed potent SDH inhibition, thus were selected for further development. Malonate ester prodrugs with different properties were characterised. Hydrolysis rates of the esters differed greatly, with tuned, labile, malonate esters releasing malonate much more rapidly. Malonate esters were taken up into cells and hydrolysed to release malonate to different extents. Additionally, mitochondria-targetedmalonatemono and diesters were developed, each differing in mitochondrial and cellular uptake andmalonate release. Targeted and nontargeted malonate esters distributed into tissues in vivo, with preliminary in vivo work carried out on IR injury models, to assess for protective effects of the compounds. In addition, the physiological role of the tricarboxylic acid cycle metabolite, itaconate, was investigated. In lipopolysaccharide stimulated macrophages, itaconate has been reported to exert its effects by inhibition of SDH however, I found itaconate was a relatively poor SDH inhibitor, indicating other mechanisms of action. Current prodrugs of itaconate have many non-specific effects, not attributable to itaconate. I therefore characterised a novel itaconate prodrug and found it to be a much better surrogate, which could be subsequently used to elucidate roles for itaconate. Overall, I have shown the importance of ester selection for the prodrug delivery of dicarboxylate molecules and developed methods to improve their biological delivery.

Hypoxic pulmonary vasoconstriction (HPV) is a local physiological mechanism in lungs that optimalises blood oxygenation during alveolar hypoxia. Arterioles in the affected region increase flow resistance which redirects blood to better ventilated parts of the lung. During global hypoxia - e.g. in high altitude or in chronic pulmonary illnessess - this mechanism doesn't work, as the blood cannot be redirected elsewhere. The pressure in pulmonary artery rises which leads to right heart hypertrophy and ultimately to cor pulmonale. This mechanism has been studied for decades, but specific signalling pathways still lack full description and therapeutical solutions are not available. This thesis offers description of selected properties of pulmonary circulation and patophysiological context of pulmonary hypertension, introduces the reader to HPV localization and signalization, and discusses its most important steps from decreased oxygen availability to vessel constriction. The practical part of this work explores Succinate dehydrogenase (SDH) - complex coupling Kreb's cycle to electron transport chain - as a primary detection site of hypoxia in pulmonary artery smooth muscle cells. We decided to test this hypothesis in isolated rat lungs by measuring if malonate (SDH inhibitor) causes vasoconstriction as...

The aim of this research was to identify the mechanisms that underpin changes in respiratory capacity during acclimation to temperature. Dark respiration, enzyme activities and leaf ultrastructure were measured from ryegrass (Lolium perenne) in controlled environmental chambers and two species of native grass (Chionochloa rubra & C. pallens) growing at different altitudinal ranges on Mount Hutt, Canterbury, New Zealand. The overall hypothesis was that the changes in both mitochondrial numbers and enzyme activity underpin the greater respiratory capacity observed in response to decreasing temperatures. Gas exchange measurements were carried out to measure rates of dark respiration (Rd) in leaves of both ryegrass and tussocks. Respiratory homeostasis (full acclimation) was achieved in ryegrass leaves but only partial acclimation in both species of tussock plants. Dark respiration rates for warm-grown ryegrass were greatly reduced compared to cool-grown grasses. Rd was lower for C. rubra growing at the base of the mountain (450m) compared to plants at a higher altitude (1060m). The dark respiration rates were also lower for C. pallens growing at 1070m than at 1600m. When comparing Rd between high and low altitude plants, it was significantly lower in low altitude plants at 450m than at 1600m. Oxygen consumption was measured in intact leaves and roots, crude mitochondria and isolated mitochondria from ryegrass to investigate whether a change in respiratory capacity was involved with changes in Rd. Mitochondrial respiratory capacity was slightly reduced in warm leaves and roots (not significantly). The respiratory capacity results from isolated mitochondria for C. rubra (at 450m and 1060m) and C. pallens (at 1070m and 1600m) were consistent with the hypothesis that plants from warm sites have lower respiratory capacity in comparison to plants from cool sites. Based on these results and those of previous studies, it was concluded that respiratory flux for any given temperature is not simply determined by maximal capacities of the respiratory apparatus but rather a combination of the availability of substrate supply, the demand for respiratory products (i.e. ATP) and/or the maximal capacity of respiratory enzymes. Utilizing transmission electron micrographs, it was found that mitochondria were significantly less abundant in warm-grown than cool-grown ryegrass mesophyll cells. Mitochondria dimensions increased slightly between the cool and warm treatment. At lower altitudes (C. rubra), there was a significant decrease in mitochondria numbers with decreasing elevation. At higher altitudes (C. pallens), there was no noticeable change in mitochondria numbers between 1070m and 1600m. It was concluded that mitochondrial abundance for the controlled and field experiments, and mitochondrial sizes in the field, were associated with changes in Rd. The maximal activities of fumarase and succinate dehydrogenase (SDH) in isolated mitochondria from leaves of ryegrass and tussock were measured spectrophotometrically. The results in the controlled experiment indicate that enzymes other than fumarase and SDH could be responsible for the increased respiratory capacity observed in cold acclimated leaves of ryegrass. However, fumarase maximal activity was significantly reduced in C. rubra at low altitude compared with C. pallens growing at high altitude - this suggests that it may be involved in the differences in respiratory capacity and Rd between the two sites. Succinate dehydrogenase did not differ significantly in response to altitude. The large difference between the two field sites for fumarase activity is comparable to the large difference in Rd and reduction in mitochondrial abundance and dimensions seen between the two sites. This supports the overall hypothesis that cool-grown plants keep up with energy demands at low temperatures by increasing enzyme concentrations/capacity. The results of this study are supportive of the hypothesis that growth in low altitudes and warm conditions will result in the reduction of Rd as a consequence of: (1) temperature sensitivity of the respiratory apparatus, resulting in the reduction of the respiratory capacities of mitochondria; (2) a reduction in mitochondria size and numbers; and as a consequence of this (3) a reduction in the activities of mitochondrial enzymes. However, these responses are species specific and vary according to the range of temperatures experienced by plants in the field and controlled environments.

The aim of this research was to identify the mechanisms that underpin changes in respiratory capacity during acclimation to temperature. Dark respiration, enzyme activities and leaf ultrastructure were measured from ryegrass (Lolium perenne) in controlled environmental chambers and two species of native grass (Chionochloa rubra & C. pallens) growing at different altitudinal ranges on Mount Hutt, Canterbury, New Zealand. The overall hypothesis was that the changes in both mitochondrial numbers and enzyme activity underpin the greater respiratory capacity observed in response to decreasing temperatures. Gas exchange measurements were carried out to measure rates of dark respiration (Rd) in leaves of both ryegrass and tussocks. Respiratory homeostasis (full acclimation) was achieved in ryegrass leaves but only partial acclimation in both species of tussock plants. Dark respiration rates for warm-grown ryegrass were greatly reduced compared to cool-grown grasses. Rd was lower for C. rubra growing at the base of the mountain (450m) compared to plants at a higher altitude (1060m). The dark respiration rates were also lower for C. pallens growing at 1070m than at 1600m. When comparing Rd between high and low altitude plants, it was significantly lower in low altitude plants at 450m than at 1600m. Oxygen consumption was measured in intact leaves and roots, crude mitochondria and isolated mitochondria from ryegrass to investigate whether a change in respiratory capacity was involved with changes in Rd. Mitochondrial respiratory capacity was slightly reduced in warm leaves and roots (not significantly). The respiratory capacity results from isolated mitochondria for C. rubra (at 450m and 1060m) and C. pallens (at 1070m and 1600m) were consistent with the hypothesis that plants from warm sites have lower respiratory capacity in comparison to plants from cool sites. Based on these results and those of previous studies, it was concluded that respiratory flux for any given temperature is not simply determined by maximal capacities of the respiratory apparatus but rather a combination of the availability of substrate supply, the demand for respiratory products (i.e. ATP) and/or the maximal capacity of respiratory enzymes. Utilizing transmission electron micrographs, it was found that mitochondria were significantly less abundant in warm-grown than cool-grown ryegrass mesophyll cells. Mitochondria dimensions increased slightly between the cool and warm treatment. At lower altitudes (C. rubra), there was a significant decrease in mitochondria numbers with decreasing elevation. At higher altitudes (C. pallens), there was no noticeable change in mitochondria numbers between 1070m and 1600m. It was concluded that mitochondrial abundance for the controlled and field experiments, and mitochondrial sizes in the field, were associated with changes in Rd. The maximal activities of fumarase and succinate dehydrogenase (SDH) in isolated mitochondria from leaves of ryegrass and tussock were measured spectrophotometrically. The results in the controlled experiment indicate that enzymes other than fumarase and SDH could be responsible for the increased respiratory capacity observed in cold acclimated leaves of ryegrass. However, fumarase maximal activity was significantly reduced in C. rubra at low altitude compared with C. pallens growing at high altitude - this suggests that it may be involved in the differences in respiratory capacity and Rd between the two sites. Succinate dehydrogenase did not differ significantly in response to altitude. The large difference between the two field sites for fumarase activity is comparable to the large difference in Rd and reduction in mitochondrial abundance and dimensions seen between the two sites. This supports the overall hypothesis that cool-grown plants keep up with energy demands at low temperatures by increasing enzyme concentrations/capacity. The results of this study are supportive of the hypothesis that growth in low altitudes and warm conditions will result in the reduction of Rd as a consequence of: (1) temperature sensitivity of the respiratory apparatus, resulting in the reduction of the respiratory capacities of mitochondria; (2) a reduction in mitochondria size and numbers; and as a consequence of this (3) a reduction in the activities of mitochondrial enzymes. However, these responses are species specific and vary according to the range of temperatures experienced by plants in the field and controlled environments.

Os feocromocitomas são tumores neuroendócrinos constituídos de células cromafins secretoras de catecolaminas e neuropeptídeos diversos, cuja manifestação clínica mais comum é a hipertensão. Doze a 24% dos tumores aparentemente esporádicos, apresentam mutações germinativas em genes até então associados a síndromes herdadas, como, RET, VHL, SDHB e SDHD. A doença de von Hippel-Lindau é causada por mutações no gene VHL. As proteínas codificadas pelos genes SDHB e SDHD fazem parte do complexo mitocondrial II e da cadeia aeróbica de transporte de elétrons. O objetivo deste projeto de pesquisa foi o rastreamento de mutações nos genes VHL, SDHB e SDHD em pacientes portadores de feocromocitoma ou, também, paraganglioma esporádicos acompanhados no Serviço de Endocrinologia do Hospital das Clínicas da FMUSP. Todos os exons dos três genes estudados foram amplificados por PCR e analisados por dHPLC. Os amplicons que apresentaram cromatogramas suspeitos ao dHPLC foram submetidos ao seqüenciamento automático. Nenhuma mutação foi encontrada no gene VHL, apenas dois polimorfismos previamente descritos no exon 1, c. -77 C>T em dois pacientes e c - 195 G>A em 58,6% do total de alelos dos pacientes estudados. No gene SDHB foram encontrados dois polimorfismos previamente descritos (c. 201-36 G>T e c.487 T>C) em quatro pacientes, uma mutação silenciosa não descrita (c.540 G>A) e uma mutação previamente descrita em portadores de feocromocitoma (c. 293 G>A). Um mesmo paciente apresentou a mutação silenciosa c.540 G>A e o polimorfismo c.201-36 G>T. No gene SDHD foram encontrados dois polimorfismos descritos (c.204 C>T e c.315-32 T>C) em um paciente cada, uma variante alélica descrita na literatura na região 3\' não codificante cuja freqüência nunca foi estudada em outras populações (c.*612 C>T) e duas substituições nunca descritas na região 3\' não codificante (c.*799 T>C e c.*803 A>G). As variantes c.*612 C>T e c.*799 T>C foram detectadas em apenas um paciente cada e não foram encontradas em 200 alelos de controles normais estudados. A variante c.*803 A>G foi encontrada em nove de 76 alelos dos 38 pacientes (11,8%) e em cinco de 200 alelos de 100 controles não afetados (2,5%), sendo, portanto, um polimorfismo significativamente mais freqüente entre os portadores de feocromocitoma ou paraganglioma. Dentre os sete pacientes portadores do polimorfismo c.*803 A>G, três pacientes heterozigotos para este polimorfismo apresentaram um segundo polimorfismo no gene SDHD, sendo que um desses pacientes também apresentava uma mutação no gene SDHB. Dentre os demais quatro pacientes, dois apresentavam o polimorfismo c.*803 A>G em homozigose. Este polimorfismo ocorre no nucleotídeo localizado na posição -1 imediatamente 5\' ao Sítio de Clivagem do pré-mRNA para que ocorra a inserção da cauda Poli(A), fundamental para a estabilidade do mRNA. A substituição da base A pela base G muito provavelmente apresenta uma repercussão funcional, pois a base A na posição -1 é considerada como a mais eficiente na promoção da clivagem do pré-mRNA, enquanto a base G é considerada a menos eficiente (ordem de eficiência de clivagem A > U > C > G). Desta forma, a possibilidade desse polimorfismo conferir susceptibilidade ao desenvolvimento do feocromocitoma e do paraganglioma não está descartada, sendo provável que outros eventos genéticos sejam necessários para promover a tumorigênese. Em conclusão, esse estudo evidenciou uma baixa freqüência de mutações nas regiões codificantes dos genes VHL (mutações não detectadas), SDHB (5,2%) e SDHD (mutações não detectadas) nessa série de pacientes com feocromocitomas e paragangliomas esporádicos, porém, encontrou um polimorfismo na região 3\' não codificante do gene SDHD significativamente mais freqüente nos portadores desses tumores que em indivíduos controles não afetados, e que, por suas características, pode estar relacionado à etiopatogenia do feocromocitoma e do paraganglioma. / Pheochromocytomas are neuroendocrine tumors composed of chromaffin cells that produce and secrete catecholamines as well as a variety of neuropeptides, whose most common clinical manifestation is arterial hypertension. Twelve to 24% of the apparently sporadic pheochromocytomas, present germline mutations in genes previously associated to inherited familiar syndromes, such as, RET, VHL, SDHB e SDHD. The von Hippel-Lindau (VHL) disease occurs upon the VHL gene mutation - a tumor suppressor gene whose product encodes complexes with other proteins leading proteic substracts to the proteolysis. The proteins encoded by the SDHD and SDHB genes are parts of the complex mitochondrial II, as well as the aerobic chain of the electron transport. The aim of the present study was the screening of mutations in the VHL, SDHB and SDHD genes in patients harboring sporadic pheochromocytoma and/or paraganglioma, followed by the Endocrinology Service of Hospital das Clínicas of the University of São Paulo School of Medicine. All the three studied gene exons were amplified by polymerase chain reaction (PCR) and were analyzed by dHPLC, which was the method used for screen mutations. The samples with altered eluting progress were directly sequenced. No mutations were found in the VHL gene, only two polymorphisms previously described in the exon 1, c. -77 C>T in two patients and c - 195 G> in 58.6% out of the total alleles of the studied patients. Two polymorphisms previously described (c. 201-36 G>T and c.487 T>C) in the SDHB gene were found in four patients, as well as silent mutation not yet described (c.540 G>A) and a mutation previously described in patients with pheochromocytoma (c. 293 G>A). A particular patient presented the silent mutation c.540 G>A and the polymorphism c.201-36 G>T. In the SDHD gene two polymorpfisms previously described (c.204 C>T and c.315-32 T>C) were found, one in each patient, as well as an allelic variant previously described in the 3\' non-coding region whose frequency has never been studied in other populations (c.*612 C>T) and two substitutions never described in the 3\' non-coding region (c.*799 T>C and c.*803 A>G). The variants c.*612 C>T and c.*799 T>C were detected in only one patient each and have not been found in 200 alleles of normal control subjects studied. The variant c.*803 A>G was found in nine out of 76 alleles from 38 patients (11.8%) and in five out of 200 alleles from 100 non-affected subjects (2.5%), being, then, a polymorphism significantly more frequent among patients with pheochromocytoma or paraganglioma. Among those seven patients with the polymorphism c.*803 A>G, three patients heterozygotous for the polymorphism presented a second polymorphism in the SDHD gene and one of those patients also presented a mutation in the SDHB gene. Out of the other four patients, two presented the polymorphism c.*803 A>G in heterozygosis. This polymorphism occurs in the nucleotide localized in the position -1 immediately 5\' to the site where the pre-mRNA is cleaved for the insertion of the poly(A) tail, which is essencial to the mRNA stability. The substitution of the A to the G probably presents a functional repercussion, because the A in the position -1 is considered as the most efficient nucleotide in the pre-mRNA cleavage promotion, while the G is considered the least efficient one (scale of cleavage efficiency A > U > C > G). Therefore, the possibility of this polymorphism be associated with susceptibility to the development of pheochromocytoma and paraganglioma is not discarded, being possible that other genetic events are necessary to promote tumorigenesis. In conclusion, this study evidenced a low frequency of mutations in the coding regions of the genes VHL (mutations not detected), SDHB (5,2%) and SDHD (mutations not detected) in this series of patients with sporadic pheochromocytomas and paragangliomas, however, a polymorphism significantly more frequent in patients harboring those tumors was found in the 3\' non-coding region of the SDHD gene and, for its specific characteristics, it can very well be related to the etiopathogenesis of the pheochromocytoma and paraganglioma

Os feocromocitomas são tumores neuroendócrinos constituídos de células cromafins secretoras de catecolaminas e neuropeptídeos diversos, cuja manifestação clínica mais comum é a hipertensão. Doze a 24% dos tumores aparentemente esporádicos, apresentam mutações germinativas em genes até então associados a síndromes herdadas, como, RET, VHL, SDHB e SDHD. A doença de von Hippel-Lindau é causada por mutações no gene VHL. As proteínas codificadas pelos genes SDHB e SDHD fazem parte do complexo mitocondrial II e da cadeia aeróbica de transporte de elétrons. O objetivo deste projeto de pesquisa foi o rastreamento de mutações nos genes VHL, SDHB e SDHD em pacientes portadores de feocromocitoma ou, também, paraganglioma esporádicos acompanhados no Serviço de Endocrinologia do Hospital das Clínicas da FMUSP. Todos os exons dos três genes estudados foram amplificados por PCR e analisados por dHPLC. Os amplicons que apresentaram cromatogramas suspeitos ao dHPLC foram submetidos ao seqüenciamento automático. Nenhuma mutação foi encontrada no gene VHL, apenas dois polimorfismos previamente descritos no exon 1, c. -77 C>T em dois pacientes e c - 195 G>A em 58,6% do total de alelos dos pacientes estudados. No gene SDHB foram encontrados dois polimorfismos previamente descritos (c. 201-36 G>T e c.487 T>C) em quatro pacientes, uma mutação silenciosa não descrita (c.540 G>A) e uma mutação previamente descrita em portadores de feocromocitoma (c. 293 G>A). Um mesmo paciente apresentou a mutação silenciosa c.540 G>A e o polimorfismo c.201-36 G>T. No gene SDHD foram encontrados dois polimorfismos descritos (c.204 C>T e c.315-32 T>C) em um paciente cada, uma variante alélica descrita na literatura na região 3\' não codificante cuja freqüência nunca foi estudada em outras populações (c.*612 C>T) e duas substituições nunca descritas na região 3\' não codificante (c.*799 T>C e c.*803 A>G). As variantes c.*612 C>T e c.*799 T>C foram detectadas em apenas um paciente cada e não foram encontradas em 200 alelos de controles normais estudados. A variante c.*803 A>G foi encontrada em nove de 76 alelos dos 38 pacientes (11,8%) e em cinco de 200 alelos de 100 controles não afetados (2,5%), sendo, portanto, um polimorfismo significativamente mais freqüente entre os portadores de feocromocitoma ou paraganglioma. Dentre os sete pacientes portadores do polimorfismo c.*803 A>G, três pacientes heterozigotos para este polimorfismo apresentaram um segundo polimorfismo no gene SDHD, sendo que um desses pacientes também apresentava uma mutação no gene SDHB. Dentre os demais quatro pacientes, dois apresentavam o polimorfismo c.*803 A>G em homozigose. Este polimorfismo ocorre no nucleotídeo localizado na posição -1 imediatamente 5\' ao Sítio de Clivagem do pré-mRNA para que ocorra a inserção da cauda Poli(A), fundamental para a estabilidade do mRNA. A substituição da base A pela base G muito provavelmente apresenta uma repercussão funcional, pois a base A na posição -1 é considerada como a mais eficiente na promoção da clivagem do pré-mRNA, enquanto a base G é considerada a menos eficiente (ordem de eficiência de clivagem A > U > C > G). Desta forma, a possibilidade desse polimorfismo conferir susceptibilidade ao desenvolvimento do feocromocitoma e do paraganglioma não está descartada, sendo provável que outros eventos genéticos sejam necessários para promover a tumorigênese. Em conclusão, esse estudo evidenciou uma baixa freqüência de mutações nas regiões codificantes dos genes VHL (mutações não detectadas), SDHB (5,2%) e SDHD (mutações não detectadas) nessa série de pacientes com feocromocitomas e paragangliomas esporádicos, porém, encontrou um polimorfismo na região 3\' não codificante do gene SDHD significativamente mais freqüente nos portadores desses tumores que em indivíduos controles não afetados, e que, por suas características, pode estar relacionado à etiopatogenia do feocromocitoma e do paraganglioma. / Pheochromocytomas are neuroendocrine tumors composed of chromaffin cells that produce and secrete catecholamines as well as a variety of neuropeptides, whose most common clinical manifestation is arterial hypertension. Twelve to 24% of the apparently sporadic pheochromocytomas, present germline mutations in genes previously associated to inherited familiar syndromes, such as, RET, VHL, SDHB e SDHD. The von Hippel-Lindau (VHL) disease occurs upon the VHL gene mutation - a tumor suppressor gene whose product encodes complexes with other proteins leading proteic substracts to the proteolysis. The proteins encoded by the SDHD and SDHB genes are parts of the complex mitochondrial II, as well as the aerobic chain of the electron transport. The aim of the present study was the screening of mutations in the VHL, SDHB and SDHD genes in patients harboring sporadic pheochromocytoma and/or paraganglioma, followed by the Endocrinology Service of Hospital das Clínicas of the University of São Paulo School of Medicine. All the three studied gene exons were amplified by polymerase chain reaction (PCR) and were analyzed by dHPLC, which was the method used for screen mutations. The samples with altered eluting progress were directly sequenced. No mutations were found in the VHL gene, only two polymorphisms previously described in the exon 1, c. -77 C>T in two patients and c - 195 G> in 58.6% out of the total alleles of the studied patients. Two polymorphisms previously described (c. 201-36 G>T and c.487 T>C) in the SDHB gene were found in four patients, as well as silent mutation not yet described (c.540 G>A) and a mutation previously described in patients with pheochromocytoma (c. 293 G>A). A particular patient presented the silent mutation c.540 G>A and the polymorphism c.201-36 G>T. In the SDHD gene two polymorpfisms previously described (c.204 C>T and c.315-32 T>C) were found, one in each patient, as well as an allelic variant previously described in the 3\' non-coding region whose frequency has never been studied in other populations (c.*612 C>T) and two substitutions never described in the 3\' non-coding region (c.*799 T>C and c.*803 A>G). The variants c.*612 C>T and c.*799 T>C were detected in only one patient each and have not been found in 200 alleles of normal control subjects studied. The variant c.*803 A>G was found in nine out of 76 alleles from 38 patients (11.8%) and in five out of 200 alleles from 100 non-affected subjects (2.5%), being, then, a polymorphism significantly more frequent among patients with pheochromocytoma or paraganglioma. Among those seven patients with the polymorphism c.*803 A>G, three patients heterozygotous for the polymorphism presented a second polymorphism in the SDHD gene and one of those patients also presented a mutation in the SDHB gene. Out of the other four patients, two presented the polymorphism c.*803 A>G in heterozygosis. This polymorphism occurs in the nucleotide localized in the position -1 immediately 5\' to the site where the pre-mRNA is cleaved for the insertion of the poly(A) tail, which is essencial to the mRNA stability. The substitution of the A to the G probably presents a functional repercussion, because the A in the position -1 is considered as the most efficient nucleotide in the pre-mRNA cleavage promotion, while the G is considered the least efficient one (scale of cleavage efficiency A > U > C > G). Therefore, the possibility of this polymorphism be associated with susceptibility to the development of pheochromocytoma and paraganglioma is not discarded, being possible that other genetic events are necessary to promote tumorigenesis. In conclusion, this study evidenced a low frequency of mutations in the coding regions of the genes VHL (mutations not detected), SDHB (5,2%) and SDHD (mutations not detected) in this series of patients with sporadic pheochromocytomas and paragangliomas, however, a polymorphism significantly more frequent in patients harboring those tumors was found in the 3\' non-coding region of the SDHD gene and, for its specific characteristics, it can very well be related to the etiopathogenesis of the pheochromocytoma and paraganglioma

No description available.

Mitochondria are essential organelles for most eukaryotic cells, containing intricate networks of numerous proteins. These include, among others, complexes I-IV of the electron transport chain. Being at the crossroads of the tricarboxylic acid cycle and the respiratory chain, mitochondrial complex II plays a key role in cellular metabolism. The protein complex, also known as succinate dehydrogenase, is capable of not only succinate oxidation and electron transfer but also contributes to the production of reactive oxygen species. Mitochondrial complex II consists of four subunits, SDHA-D, and four dedicated protein assembly factors SDHAF1-4 that participate in complex II biogenesis. Mutations and epigenetic modulations of genes coding for succinate dehydrogenase subunits or assembly factors are associated with pathological conditions such as neurodegenerative diseases, or may result in tumor formation. However, inborn complex-II-linked mitochondrial pathologies are rather understudied, compared to diseases with causative errors of other mitochondrial complexes, presumably due to the fact that none of complex II subunits is encoded in the mitochondrial genome. Recent studies have shown that impairment of mitochondrial complex II function or assembly leads to accumulation of alternative assembly forms...